

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicant	: Viswanathan SRINIVASAN et al.	Confirmation No. 4898
		Group Art Unit: 1615
Appl. No:	: 10/798,884	
		Examiner: Sasan, Aradhana
Filed	: March 12, 2004	
For	: DOSAGE FORM CONTAINING A MORPHINE DERIVATIVE AND ANOTHER DRUG	

STATEMENT OF INTERVIEW

Commissioner for Patents
U.S. Patent and Trademark Office
Customer Service Window, Mail Stop **Appeal Brief-Patents**
Randolph Building
401 Dulany Street
Alexandria, VA 22314

Sir:

Applicants express appreciation for the courtesies extended by Supervisory Patent Examiner Woodward during October 16, 2008 telephone calls with Applicants' representative Arnold Turk.


During the telephone calls, the Notice of Non-Compliant Appeal Brief mailed September 30, 2008 was discussed. The Supervisory Patent Examiner indicated that the reason for the alleged non-compliance with the provisions of 37 CFR 41.37(c) was that Applicants' Appeal Brief did not contain any indication that Applicants are willing to file one or more Terminal Disclaimers to address the obviousness-type double patenting rejections of record. In view thereof, Applicants' representative proposed to incorporate the following statement into the Appeal Brief:

Upon indication of allowable subject matter, Appellants will file one or more Terminal Disclaimers which address all double patenting rejections which may still be warranted.

The Supervisory Patent Examiner confirmed that this statement is sufficient for complying with the provisions of 37 CFR 41.37(c).

Should there be any questions, please call the undersigned at the telephone number indicated below.

Respectfully Submitted,
Viswanathan SRINIVASAN et al.



Arnold Turk
Reg. No. 33,094

October 17, 2008
GREENBLUM & BERNSTEIN, P.L.C.
1950 Roland Clarke Place
Reston, VA 20191
(703) 716-1191